OBJECTIVES : We performed an initial analysis for health economic impact of ongoing randomized controlled trial of Twin Precision Treatment, a novel whole-body digital twin enabled precision nutrition for reversing diabetes.

METHODS : We evaluated patients (n=33) who completed 4 months longitudinal follow up and modeled the parameters for the health economics from the published literature to benchmark with our results

RESULTS : Mean age, duration of diabetes was 40 (±8.8) and 2.8 (±2.4) years, respectively. 19 and 13 patients achieved initial partial (HbA1c range 5.7-6.4 %) and complete (HbA1c < 5.7%) remission of diabetes, respectively. All patients achieved HbA1c less than 7%. All 12 patients on OAD did not need ongoing OAD, 2 patients on insulin did not need it at 90 days. There was a statistically significant improvement in HbA1c % (8.7 ± 1.5 to 5.6 ± 0.51; decrease -3.1, p<0.0001), body weight (79 ± 12 to 70 ± 11; decrease -9.1 kg, p=0.0014), BMI (28 ± 3.3 to 24 ± 2.9; decrease -3.4 kg/m2, p<0.0001), Systolic BP (131 ± 13 to 119 ± 12; decrease -12 mmHg, p=0.0002), Diastolic BP (89 ± 11 to 79 ± 8; decrease -10 mmHg, p<0.0001), HDL-C (33 ± 5.1 to 37 ± 8.2; increase 4.1 mg/dl, p=0.0191), TG (224 ± 99 to 130 ± 93; decrease -94 mg/dl, p<0.0001). The modeled adjusted health cost savings entail a cumulative annual per patient savings of USD 7800 attributed to the improvement in BMI, HbA1c and blood pressure control .

CONCLUSIONS : The results indicate that an efficacious early technological intervention, through digital twin technology, powered by Internet of Things and Artificial Intelligence, as a modality to enable reversal of diabetes. We postulate that the substantial cost savings and propensity for decrease in medical claim induced by the Twin Precision Treatment deserves a larger exploration by the health care payers